New pharmaceuticals for unresectable Or metastatic malignant melanoma
This KCE has read for you was prepared by Lorena San Miguel and Nadia Benahmed
- The Norwegian Knowledge Centre for the Health Services assessed in November 2015 the effectiveness and cost-effectiveness of seven new drugs for the treatment of unresectable or metastatic malignant melanoma in the adult population. Their review included evidence from 17 RCTs.
- For overall survival (over a 2 year time horizon), nivolumab or pembrolizumab as monotherapies as well as the combinations of nivolumab+ipilimumab,
vemurafenib+cobimetinib and dabrafenib+trametinib have the highest probabilities of being superior to the other treatment strategies.
- For safety, nivolumab and pembrolizumab have the lowest probability of serious adverse events but the quality of the evidence was rated as low.
- The cost-effectiveness evaluation including all interventions showed that at list prices in Norway, all new treatments had ICERs above € 100 000 per QALY.
KCE has read for you synthesises a recently published high-quality systematic review or health technology assessment with relevance for the Belgian health system.
The original publication was appraised and contextualised by KCE researchers. KCE has read for you is not based on original research conducted by KCE.
More details on methodology can be found on the KCE website.
This document includes
- Key findings of the publication under evaluation
- A contextualisation within the Belgian healthcare system
- Detailed descriptions
Trustworthy original publication
The methodological quality of the systematic review was assessed with the AMSTAR tool.